Natera NTRA 深 滬
等待開盤 10-03 09:30:00 美东时间
160.21
-1.400
-0.87%
華盛通- 最 高161.91
- 今 開161.91
- 成交量 104.24万股
- 最 低 157.425
- 昨 收 161.61
- 總市值 219.49亿
- 52周最高 183.00
- 市盈率 靜 --
- 換手率 0.76%
- 52周最低 117.27
- 委 比 -44.83%
- 總股本 1.37亿
- 歷史最高 183.00
- 量 比 0.79
- 振 幅 2.78%
- 歷史最低 6.52
- 每 手 1
- 風險率 15.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Here's How Much $1000 Invested In Natera 5 Years Ago Would Be Worth Today
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 2.92%...
09-25 06:45
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Premier Set For Private Ownership, Eyes Growth Push
Premier Inc. to be acquired by Patient Square Capital at $28.25 per share, offering shareholders a 23.8% premium.
09-22 21:11
If You Invested $100 In Natera Stock 5 Years Ago, You Would Have This Much Today
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 8.4% ...
09-16 06:30
Cuba hit by nationwide blackout as grid collapses again
Cuba’s fragile power grid suffered its fourth nationwide collapse in less than a year on Wednesday, leaving the island’s 10 million residents without electricity. Officials said the system went down j...
09-11 00:36
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initi...
08-30 05:00
NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims
NeoGenomics wins a North Carolina court ruling invalidating key Natera patents, clearing the way for its RaDaR ST assay and boosting investor sentiment.
08-30 01:04
NeoGenomics rallies after court win in Natera patent dispute
NeoGenomics (NASDAQ:NEO) shares climbed ~20% in the premarket on Friday after the company announced a major victory in a legal battle over a patent dispute with its rival cancer test developer Natera ...
08-29 20:45
NeoGenomics Secures Court Ruling Invalidating Natera's Patents; Case Dismissed With Prejudice
– NeoGenomics wins summary judgment in patent infringement lawsuit against Natera; Court rules Natera's patents are invalid for claiming ineligible subject matter– NeoGenomics remains free to make, use, sell, and promote
08-29 19:11
